Design and manufacture of monoclonal antibodies for radioimmunotherapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 4, 2004, Pages 258-266

  Hale, Geoff ^a   Berrie, E ^a   Bird, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Monoclonal antibodies; Radioimmunotherapy; Radiolabelling

Indexed keywords

IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN A; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ANTIBODY; TOSITUMOMAB I 131; RADIOISOTOPE; RECOMBINANT PROTEIN;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING AFFINITY; BIOREACTOR; CHO CELL; COLUMN CHROMATOGRAPHY; CULTURE MEDIUM; CULTURE OPTIMIZATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURIFICATION; DRUG STABILITY; EXPRESSION VECTOR; FERMENTATION OPTIMIZATION; FERMENTATION TECHNIQUE; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOREACTIVITY; ION EXCHANGE CHROMATOGRAPHY; ISOTOPE LABELING; MANDATORY PROGRAM; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MURINE LEUKEMIA VIRUS; NONHUMAN; PATENT; PH; PRACTICE GUIDELINE; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RETROVIRUS INFECTION; REVIEW; VALIDATION PROCESS; VIRAL CONTAMINATION; ANIMAL; BIOSYNTHESIS; DRUG INDUSTRY; GENETICS; METHODOLOGY; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; ISOTOPE LABELING; PROTEIN ENGINEERING; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS;

EID: 15944367464     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Clark M, Cobbold S, Hale G, Waldmann H. Advantages of rat monoclonal antibodies. Immunol Today 1983:4:100-1.
2. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-11.
3. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999;29:2613-24.
4. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J et al. High resolution mapping of the bindin site on human IgG1 for Fc gamma RI, Fc: gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001:276:6591-604.
5. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999;29:2819-25.
6. Sato K, Ohtomo T, Hirata Y, Saito H, Matsuura T, Akimoto T et al. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Hum Antibodies Hybridomas 1996;7:175-83.
7. Endo T, Wright A, Morrison SL, Kobata A. Glycosylation of the variable region of immunoglobulin G: site specific maturation of the sugar chains. Mol Immunol 1995;32:931-40.
8. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995:60: 847-53.
9. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993;30:105-8.
10. Perkins M, Theiler R, Lunte S, Jeschke M. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res 2000;17:1110-7.
11. Lazar AC, Kloczewiak MA, Mazsaroff I. Matrix-assisted laser desorption/ ionization mass spectrometry for the evaluation of the C-terminal lysine distribution of a recombinant monoclonal antibody. Rapid Commun Mass Spectrom 2004;18:239-44.
12. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V et al. Specific cleavage of immunoglobulin G by copper ions. Int J Pept Protein Res 1996;48:48-55.
13. Smith M, Riveros-Rojas V. Immunoglobulins stabilized with a chelator of copper ions. United States Patent number 5,654,403, 5 Aug 1997.
14. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Charmow SM. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 2003;20:1952-60.
15. Wood CR, Dorner AJ, Morris GE, Alderman EM, Wilson D, O'Hara Jr RM et al High level synthesis of immunoglobulins in CHO cells. J Immunol 1990;145:3011-6.
16. Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (NY) 1991;9:64-8.
17. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (NY) 1992;10:169-75.
18. Humphreys DP, Glover DJ. Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr Opin Drug Discov Devel 2001;4:172-85.
19. Verma R, Bolet E, George AJT. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Meth 1998:216:165-81.
20. Cockett MI, Bebbington CR, Yarranton GT. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (NY) 1990;8:662-7.
21. Doral H, Moore GP. The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes. J Immunol 1987:139:4232-41.
22. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP) and Committee for Veterinary Medicinal Products (CVMP). Note for guidance on Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products EMEA/ 410/01 Rev 2, 9 Dec 2002.
23. Food and Drug Administration, Center for Biologics Evaluation and Research. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, 28 Feb 1997.
24. Food and Drug Administration, Center for Biologics Evaluation and Research. Points to Consider In the Characterisation of cell lines used to produce biologicals. 1 Aug 1993
25. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Virus Validation Studies: The design, contribution and Interpretation of studies validating the Inactivation and removal of viruses. CPMP/BWP/268/95. revised 14 Feb 1996.
26. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). ICH Topic Q5A, step 4 Consensus Guideline. Note for Guidance on Quality if Biotechnology Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95. 4 Mar 1997.
27. Shepherd AJ, Wilson NJ, Smith KT. Characterisation of endogenous retrovirus in rodent cell lines used for production of biologicals. Biologicals 2003;31:251-60.
28. Cobbold SP. Large-scale production of monoclonal antibodies. http://users.path.ox.ac.uk/~scobbold/tig/mprod.html
29. Phillips J, Drumm A, Harrison P, Bird P, Bhamra K, Berrie E et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001;3:233-42.
30. Houe H. Epidemiological features and economical importance of bovine virus diarrhoea virus (BVDV) infections. Vet Microbiol 1999;64:89-107.
31. House C, House JA, Yedloutschnig RJ. Inactivation of viral agents in bovine serum by gamma irradiation. Can J Microblol 1990;36:737-40.
32. Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002;42:1005-10.
33. Kurth J, Waldmann R, Heith J, Mausbach K, Burian R. Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation. Dev Biol Stand 1999;99:111-8.
34. Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R. Improved fermentation processes for NSO cell lines expressing human antibodies and glutamine synthetase. Biotechnol Prog 2003;19:175-8.
35. Trebak M, Chong JM, Herlyn D, Speicher DW. Efficient laboratory-scale production of monoclonal antibodies using membrane-based high-density cell culture technology. J Immunol Methods 1999;230:59-70.
36. Singh V. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 1999;30:149-58.
37. Gagnon P. Purification tools for monoclonal antibodies. pub. Validated Biosystems Inc, Tucson AZ, USA, 1996.
38. Hale G, Drumm A, Harrison P, Phillips J. Repeated cleaning of Protein A affinity column with sodium hydroxide. J Immunol Meth 1994;171:15-21.
39. Graf EG, Jander E, West A, Pora H, Aranha-Creado H. Virus removal by filtration. Dev Biol Stand 1999;99:89-94.
40. Darling A. Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol Biotechnol 2002;21:57-83.
41. Aranha Creado H, Peterson J, Huang PY. Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter. Biologicals 1998:26:167-72.
42. Kamat MS, Tolman GL, Brown JM. Formulation development of an antifibrin monoclonal antibody radiopharmaceutical. Pharm Biotechnol 1996;9:343-64.
43. Eisenhut M, Lehmann WD, Becker W, Behr T, Elser H, Strittmatter W et al. Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immuno-reactivity and kit formulation. J Nucl Med 1996;37:362-70.
44. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal anti-bodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
45. 131I-chimeric L6 monoclonal antibody and comparison to in vivo tumor localization. J Immunol Methods 1994:173:191-201.